FDA Proposes Excluding Novo and Lilly Weight-Loss Drugs From Bulk Compounding List

sciencepharmabusinesslaw 2 posts · 2 accounts

The FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying there is no clinical need for outsourcing facilities to compound them from bulk substances when approved versions are available. The move would exclude Novo and Lilly weight-loss drugs from the bulk compounding list, and public comments on the proposal run through June 29.

From the sources (2 posts)

@wallstengine

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying there is no clinical need for outsourcing facilities to compound them from bulk substances when approved versions are available. Public commen

@cnbc

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

Market impact

48 medium

NVO LLY HIMS

Why it matters: FDA proposing to bar outsourcing facilities from compounding semaglutide/tirzepatide/liraglutide from bulk removes a cheap competitive substitute, protecting Novo and Lilly branded GLP-1 revenue while hurting compounding-reliant telehealth sellers like Hims.

At publish time: Headline itself flags a favorable regulatory action ("win for the companies") that walls off the compounded-GLP-1 competitive channel for Novo and Lilly.

model confidence: medium

What happened next

1–2 weeks later

played out moved up

NVO/LLY gained on the proposal and NVO rose ~9% weeks later on Wegovy-pill data; HIMS fell ~7% initially but pivot news muddied its path.

based on follow-up coverage

Follow-up coverage

No follow-up coverage matched this story.

Exxon and Chevron Beat Estimates as Iran War Threatens Oil Supply Trump Says EU Car and Truck Tariffs Will Rise to 25% Next Week